Is Equillium, Inc. (EQ) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.4% / 30% | 20.9% / 30% | 1.1% / 30% | 3.36% / 5% | ✓ HALAL |
| DJIM | 0.4% / 33% | 20.9% / 33% | 1.1% / 33% | 3.36% / 5% | ✓ HALAL |
| MSCI | 1.5% / 33% | 88.2% / 33% | 4.5% / 33% | 3.36% / 5% | ✗ NOT HALAL |
| S&P | 0.4% / 33% | 20.9% / 33% | 1.1% / 33% | 3.36% / 5% | ✓ HALAL |
| FTSE | 1.5% / 33% | 88.2% / 33% | 4.5% / 50% | 3.36% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -94.0% | |
| Return on Assets (ROA) | -51.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$19M |
| Free Cash Flow | -$19M |
| Total Debt | $384,000 |
| Debt-to-Equity | 2.5 |
| Current Ratio | 10.6 |
| Total Assets | $26M |
Price & Trading
| Last Close | $2.06 |
| 50-Day MA | $1.71 |
| 200-Day MA | $1.23 |
| Avg Volume | 627K |
| Beta | 1.8 |
|
52-Week Range
$0.27
| |
About Equillium, Inc. (EQ)
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ulcerative colitis. The company also develops EQ101, first-in-class, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which completed Phase 1/2 to treat cutaneous T cell lymphoma. It serves its products to gastroenterology, dermatology, hematology, transplant science, rheumatology, pulmonology, and oncology areas. The company has a collaboration and license agreement with Biocon SA to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit itolizumab (EQ001) and any pharmaceutical composition or preparation containing or comprising itolizumab (EQ001) that uses Biocon technology or Biocon know-how, or collectively, a Biocon Product. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Purification Calculator
As a halal stock with 3.36% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Equillium, Inc. (EQ) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Equillium, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Equillium, Inc.'s debt ratio?
Equillium, Inc.'s debt ratio is 0.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.5%.
Does Equillium, Inc. require dividend purification?
Yes, Equillium, Inc. has an impermissible income ratio of 3.36%, which means 3.36% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Equillium, Inc.'s key financial metrics?
Equillium, Inc. has a market capitalization of $119M, and revenue of $41M. Return on equity stands at -94.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.